Chardan analyst Gbola Amusa raised the firm’s price target on Synlogic to $10 from $5 and keeps a Buy rating on the shares. Synlogic, trading at a 13% discount to cash, is not priced for the potential of its three “possible and different” clinical-stage readouts in 2021, Amusa tells investors in a research note. The analyst made the company a “Chardan Top Pick for 2021.” Though the stock traded down on the failure of SYNB1020 in cirrhosis, that asset faced two issues: whether SYNB1020 can modulate a toxic metabolite, and whether modulating the toxic metabolite matters, says Amusa. For current Synlogic’s metabolic assets, the biology is relatively well understood, so that only the first issue is a main controversy for 2021, the analyst adds. Amusa believes Synlogic has a “differentiated” genetically-engineered live biotherapeutic product platform to improve clinical outcomes in target areas of oncology and disorders of metabolism.